Search
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigationalEnzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 20...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnFormestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or pro...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .
Categories: P-glycoprotein inducers, P-glycoprotein substratesIndenolol
go.drugbank.com/drugs/DB08952ApprovedWithdrawnIndenolol is a drug of the beta-adrenergic blocker class.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesFendiline
go.drugbank.com/drugs/DB08980ApprovedWithdrawnFendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIbrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibruti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTechnetium Tc-99m sestamibi
go.drugbank.com/drugs/DB09161ApprovedInvestigationalTechnetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) l...
Categories: P-glycoprotein substratesLobeglitazone
go.drugbank.com/drugs/DB09198InvestigationalLobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. B...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsCiglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones....
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedTolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment fo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates